Q32 Bio CMO resigns; appoints Adrien Sipos as Interim CMO

Q32 Bio Inc.

Jason Campagna, M.D., Ph.D. resigns as Chief Medical Officer, effective July 9, 2025.
Adrien Sipos, M.D., Ph.D. appointed Interim CMO, effective July 9, 2025; over 25 years I&I experience.
Dr. Sipos to lead advancement of bempikibart in SIGNAL-AA Phase 2a trial for alopecia areata.
Topline results from Part B of SIGNAL-AA expected in first half of 2026.
Prior roles include Biogen, Sanofi Genzyme, Eli Lilly, and President/CMO at PRAXICO.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.